|
| 38088562 | High fusion and cytopathy of SARS-CoV-2 variant B.1.640.1. | J Virol | 2024 |
| 36853052 | Exposure to Secreted Bacterial Factors Promotes HIV-1 Replication in CD4[+] T Cells. | Microbiol Spectr | 2023 |
| 37558883 | Dissecting human population variation in single-cell responses to SARS-CoV-2. | Nature | 2023 |
| 37549192 | Modeling the kinetics of the neutralizing antibody response against SARS-CoV-2 variants after several administrations of Bnt162b2. | PLoS Comput Biol | 2023 |
| 37155897 | Complement contributes to antibody-mediated protection against repeated SHIV challenge. | Proc Natl Acad Sci U S A | 2023 |
| 37347417 | Estimated protection against COVID-19 based on predicted neutralisation titres from multiple antibody measurements in a longitudinal cohort, France, April 2020 to November 2021. | Euro Surveill | 2023 |
| 37249912 | Polyfunctionality of broadly neutralizing HIV-1 antibodies. | Curr Opin HIV AIDS | 2023 |
| 37434700 | IFITM1 inhibits trophoblast invasion and is induced in placentas associated with IFN-mediated pregnancy diseases. | iScience | 2023 |
| 37398037 | Antiviral activities of sotrovimab against BQ.1.1 and XBB.1.5 in sera of treated patients. | medRxiv | 2023 |
| 37196656 | Complement-dependent mpox-virus-neutralizing antibodies in infected and vaccinated individuals. | Cell Host Microbe | 2023 |
| 36788246 | Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies. | Nat Commun | 2023 |
| 34606831 | The Mechanism and Consequences of SARS-CoV-2 Spike-Mediated Fusion and Syncytia Formation. | J Mol Biol | 2022 |
| 35549549 | Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody. | Proc Natl Acad Sci U S A | 2022 |
| 35410989 | Transient viral exposure drives functionally-coordinated humoral immune responses in HIV-1 post-treatment controllers. | Nat Commun | 2022 |
| 35801637 | Modelling the response to vaccine in non-human primates to define SARS-CoV-2 mechanistic correlates of protection. | Elife | 2022 |
| 35769882 | C910 chemical compound inhibits the traffiking of several bacterial AB toxins with cross-protection against influenza virus. | iScience | 2022 |
| 35789859 | Y RNAs are conserved endogenous RIG-I ligands across RNA virus infection and are targeted by HIV-1. | iScience | 2022 |
| 35862713 | Species-Specific Molecular Barriers to SARS-CoV-2 Replication in Bat Cells. | J Virol | 2022 |
| 36434007 | Defective activation and regulation of type I interferon immunity is associated with increasing COVID-19 severity. | Nat Commun | 2022 |
| 36415455 | Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies. | bioRxiv | 2022 |
| 36450283 | Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron BA.2, BA.4, and BA.5 in patients receiving monoclonal antibodies. | Cell Rep Med | 2022 |
| 35866628 | Tracking receptor motions at the plasma membrane reveals distinct effects of ligands on CCR5 dynamics depending on its dimerization status. | Elife | 2022 |
| 36228619 | Duration of BA.5 neutralization in sera and nasal swabs from SARS-CoV-2 vaccinated individuals, with or without omicron breakthrough infection. | Med | 2022 |
| 36093378 | The FDA-approved drug Auranofin has a dual inhibitory effect on SARS-CoV-2 entry and NF-κB signaling. | iScience | 2022 |
| 35891947 | Neutralising antibody responses to SARS-CoV-2 omicron among elderly nursing home residents following a booster dose of BNT162b2 vaccine: A community-based, prospective, longitudinal cohort study. | EClinicalMedicine | 2022 |
| 35891471 | Kinetics of the SARS-CoV-2 Antibody Avidity Response Following Infection and Vaccination. | Viruses | 2022 |
| 36121299 | The Spike-Stabilizing D614G Mutation Interacts with S1/S2 Cleavage Site Mutations To Promote the Infectious Potential of SARS-CoV-2 Variants. | J Virol | 2022 |
| 35290827 | Fusogenicity and neutralization sensitivity of the SARS-CoV-2 Delta sublineage AY.4.2. | EBioMedicine | 2022 |
| 35016199 | Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. | Nature | 2022 |
| 35185909 | Robust and Functional Immune Memory Up to 9 Months After SARS-CoV-2 Infection: A Southeast Asian Longitudinal Cohort. | Front Immunol | 2022 |
| 35281046 | Case Report: Evolution of Humoral and Cellular Immunity in Two COVID-19 Breakthrough Infections After BNT162b2 Vaccine. | Front Immunol | 2022 |
| 35181769 | Towards SARS-CoV-2 serotypes? | Nat Rev Microbiol | 2022 |
| 35150193 | Severe relapse of SARS-CoV-2 infection in a kidney transplant recipient with negative nasopharyngeal SARS-CoV-2 RT-PCR after rituximab. | Am J Transplant | 2022 |
| 35115533 | Phagocytosis by an HIV antibody is associated with reduced viremia irrespective of enhanced complement lysis. | Nat Commun | 2022 |
| 34905598 | Anti-CD38 therapy impairs SARS-CoV-2 vaccine response against alpha and delta variants in patients with multiple myeloma. | Blood | 2022 |
| 35110562 | Broadly neutralizing anti-HIV-1 antibodies tether viral particles at the surface of infected cells. | Nat Commun | 2022 |
| 35082297 | Low CCR5 expression protects HIV-specific CD4+ T cells of elite controllers from viral entry. | Nat Commun | 2022 |
| 35022159 | Immunogenicity of BNT162b2 vaccine against the Alpha and Delta variants in immunocompromised patients with systemic inflammatory diseases. | Ann Rheum Dis | 2022 |
| 35231463 | A fourth dose of the mRNA-1273 SARS-CoV-2 vaccine improves serum neutralization against the Delta variant in kidney transplant recipients. | Kidney Int | 2022 |
| 35230385 | Epitope convergence of broadly HIV-1 neutralizing IgA and IgG antibody lineages in a viremic controller. | J Exp Med | 2022 |
| 35104884 | COVID-19 outbreak in vaccinated patients from a haemodialysis unit: antibody titres as a marker of protection from infection. | Nephrol Dial Transplant | 2022 |
| 35322239 | Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies. | Nat Med | 2022 |
| 33288662 | IgA dominates the early neutralizing antibody response to SARS-CoV-2. | Sci Transl Med | 2021 |
| 33522642 | Syncytia formation by SARS-CoV-2-infected cells. | EMBO J | 2021 |
| 33851216 | Sera Neutralizing Activities Against Severe Acute Respiratory Syndrome Coronavirus 2 and Multiple Variants 6 Months After Hospitalization for Coronavirus Disease 2019. | Clin Infect Dis | 2021 |
| 33767144 | Quantitative characterization of extracellular vesicle uptake and content delivery within mammalian cells. | Nat Commun | 2021 |
| 33791693 | Phospholipidosis is a shared mechanism underlying the in vitro antiviral activity of many repurposed drugs against SARS-CoV-2. | bioRxiv | 2021 |
| 33899033 | Asymptomatic and symptomatic SARS-CoV-2 infections elicit polyfunctional antibodies. | Cell Rep Med | 2021 |
| 33693749 | Sex Differences in the Evolution of Neutralizing Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2. | J Infect Dis | 2021 |
| 33860747 | SARS-CoV-2 infection in schools in a northern French city: a retrospective serological cohort study in an area of high transmission, France, January to April 2020. | Euro Surveill | 2021 |